Hb is low and some subcutaneous injections of EPO keeps it stable. Rest tests are in range including spleen/liver/kidney.
Starting O today in critical care as my doc wants to be extra careful. Already on A past one week. Will be starting V after 15 days. This is some new protocol received from MD Anderson Texas.
Any tips???
Written by
Soultouch
To view profiles and participate in discussions please or .
I think this is one of the most powerful combinations available attacking CLL from different and complimentary pathways. In general well tolerated but not necessarily without hiccups. You are in great hands and they are very able to deal with whatever may come your way. You can read my profile . Finished this combination 2.5 years ago and still uMRD with blood tests every 3 months.
Hello HeikoAm not at MDA but under a CLL specialist who is connected with best trials going on at MDA. The good part is that we have one of the best team overlooking the case & the observation is amazing.
Trial of O went smoothly & now we will finish the main course by tomorrow morning. Hopefully that goes well too!!
Your case looks motivating & so does Aussieneil’s. Am positive 🤞
Ok my doc just came. Blood reports look ok. No neutropenia yet. Getting discharged as no side effects experienced in 24 hours. Now next admission will be in 2 weeks for V ramp up. Hopefully all good happens till then. Neutrophils 3.2, platelets 195000, hb is still low (wonder why?).
Glad all is going well so far. In June I finished a one year treatment plan with obinutuzumab and venetoclax. It was smooth journey; hope yours is the same. I am now in remission. I was hospitalized for first V dose and also the first ramp up. No problems eith time. These are great drugs; we are blessed to have them.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.